摘要
尽管BNP/NT-proBNP已成为心力衰竭患者诊断及预后判断的"金标准" (ⅠA级推荐)。但近几年的研究发现以前对BNP/NT-proBNP检测结果的认识有些是错误的,临床和检验医师需要了解这些新进展,以便在临床实践中更恰当地应用BNP/NT-proBNP。今后随着利钠肽相关新药的逐步使用,利钠肽家族相关片段的检测将更加重要。
Although BNP/NT-proBNP has been widely accepted as the gold standard biomarker for the diagnosis and prognosis of heart failure (recommendation level: I A) , the latest studies show that some of the previous knowledge of the test results of BNP/NT-proBNP are wrong. It is important for clinical and laboratory physicians to understand the latest progress on natriuretic peptide family in order to use BNP/NT- proBNP more properly. In the future, as the new drugs, which work via natriuretic peptide family, be used widely in patients, the test of natriuretic peptide family will become more important.
出处
《中华检验医学杂志》
CAS
CSCD
北大核心
2017年第6期414-416,共3页
Chinese Journal of Laboratory Medicine
关键词
心力衰竭
利钠肽
脑
肽碎片
脑啡肽酶
血管紧张素受体拮抗剂
Heart failure
Natriuretic peptide, brain
Peptide fragments
Neprilysin
Angiotensin receptor antagonists